<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04165993</url>
  </required_header>
  <id_info>
    <org_study_id>KN026-201</org_study_id>
    <nct_id>NCT04165993</nct_id>
  </id_info>
  <brief_title>Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast Cancer</brief_title>
  <official_title>Phase II Study of Efficacy and Safety Evaluation of KN026 Monotherapy or Combination Therapy in Patients With HER2 Expressing or Positive Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Alphamab Biopharmaceuticals Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Alphamab Biopharmaceuticals Co., Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, three-cohort phase 2 study of KN026 in subjects with advanced breast&#xD;
      Cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      KN026 is an anti-HER2 bispecific antibody that can simultaneously bind two non-overlapping&#xD;
      epitopes of HER2, leading to a dual HER2 signal blockade.The HER2- positive mBC subjects&#xD;
      without systemic treatment will be enrolled in cohort 1 and received 30 mg/kg KN026 and&#xD;
      docetaxol. The HER2 low expression and hormone-receptor positive mBC subjects failed standard&#xD;
      chemotherapy and hormone therapy will be enrolled in cohort 2 and received 30 mg/kg KN026&#xD;
      monotherapy. The HER2 low expression and hormone-receptor negative/weak positive mBC subjects&#xD;
      failed standard chemotherapy will be enrolled in cohort 3 and received 30 mg/kg KN026 and 5&#xD;
      mg/kg KN046&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 31, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Throughout the duration of the study; up to 2 years</time_frame>
    <description>Objective response rate (ORR) per RECIST 1.1 criteria according to investigators assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Duration of response (DOR) per RECIST 1.1 criteria according to investigators assessment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with adverse events (AEs), serious adverse events (SAEs) and AEs of special interest</measure>
    <time_frame>Throughout the duration of the study</time_frame>
    <description>AEs, SAEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS) rates</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>Progression free survival (PFS) rates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS) rates</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>Overall survival (OS) rates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>durable benefit rate (DBR)</measure>
    <time_frame>DBR calculated as the proportion of subjects with best overall response of CR, PR, or SD ≥24 weeks</time_frame>
    <description>durable benefit rate (DBR)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Concurrent chemotherapy and KN026</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KN026 combined with docetaxol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KN026 monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KN026 monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A combination treatment of KN026 and KN046</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KN026 combined with KN046</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Concurrent chemotherapy and KN026</intervention_name>
    <description>30 mg/kg Q3W KN026 75 mg/m2 docetaxol</description>
    <arm_group_label>Concurrent chemotherapy and KN026</arm_group_label>
    <other_name>docetaxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KN026 monotherapy</intervention_name>
    <description>30 mg/kg Q3W KN026</description>
    <arm_group_label>KN026 monotherapy</arm_group_label>
    <other_name>KN026</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KN026 combination</intervention_name>
    <description>30 mg/kg Q3W KN026 5 mg/kg Q3W KN046</description>
    <arm_group_label>A combination treatment of KN026 and KN046</arm_group_label>
    <other_name>KN046</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female subject &gt;= 18 years&#xD;
&#xD;
          -  Histologically/cytologically confirmed, locally advanced unresectable or metastatic&#xD;
             breast cancer&#xD;
&#xD;
          -  ECOG score 0 or 1&#xD;
&#xD;
          -  Life expectancy &gt;3 months&#xD;
&#xD;
          -  According to the definition of RECIST1.1, the patient has at least one measurable&#xD;
             lesion&#xD;
&#xD;
          -  Adequate organ function prior to start treatment with KN026&#xD;
&#xD;
          -  Able to understand, voluntarily participate and willing to sign the ICF&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Accepted any other anti-tumor drug therapies within 4 weeks before fist dose&#xD;
&#xD;
          -  Accepted radiotherapy within 4 weeks before enrollment&#xD;
&#xD;
          -  Subjects are eligible with clinically controlled and stable neurologic function &gt;= 4&#xD;
             weeks, which is no evidence of CNS disease progression; Subjects with spinal cord&#xD;
             compression and cancerous meningitis are not eligible&#xD;
&#xD;
          -  Pregnant or nursing females；or intend pregnancy within this study period or within 6&#xD;
             monthes after the end of this study&#xD;
&#xD;
          -  History of immunodeficiency, including HIV positive or other acquired, congenital&#xD;
             immunodeficiency disease, or a history of organ transplantation&#xD;
&#xD;
          -  History of immunodeficiency, including HIV positive or other acquired, congenital&#xD;
             immunodeficiency disease, or a history of organ transplantation&#xD;
&#xD;
          -  Cavity effusion (pleural effusion, ascites, pericardial effusion, etc.) are not well&#xD;
             controlled, and need locally treatment or repeated drainage&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Qingyuan Zhang, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Harbin Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 1, 2019</study_first_submitted>
  <study_first_submitted_qc>November 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2019</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

